N@N

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

The article from Insider Monkey discusses why Intellia Therapeutics (NTLA) is considered the worst ARK stock to buy according to short sellers. Intellia Therapeutics, a company focused on developing CRISPR-based gene editing therapies, has been highlighted due to its high short interest, with 16.5% of its float being sold short. This skepticism stems from concerns over the company's ability to successfully commercialize its therapies, the competitive landscape in gene editing, and the inherent risks associated with clinical trials and regulatory approval processes. Despite ARK Invest's Cathie Wood's optimism about the potential of gene-editing technologies, short sellers are betting against NTLA due to these uncertainties and the stock's significant volatility. The article also notes that while Intellia has promising candidates in its pipeline, the path to market remains fraught with challenges, contributing to the bearish outlook from short sellers.

Read the Full Insider Monkey Article at:
[ https://www.insidermonkey.com/blog/why-intellia-therapeutics-ntla-is-the-worst-ark-stock-to-buy-according-to-short-sellers-1405733/ ]